Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy

Tumor necrosis factor alpha (TNFα) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNFα has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages, dendritic cells, natural killer (NK) cells, and B...

ver descrição completa

Detalhes bibliográficos
Autores: Mercogliano, María Florencia, Bruni, Sofia, Mauro, Florencia Luciana, Elizalde, Patricia Virginia, Schillaci, Roxana
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Argentina
Recursos:Consejo Nacional de Investigaciones Científicas y Técnicas
Repositorio:CONICET Digital (CONICET)
Idioma:inglés
OAI Identifier:oai:ri.conicet.gov.ar:11336/137148
Acesso em linha:http://hdl.handle.net/11336/137148
Access Level:acceso abierto
Palavra-chave:ADOPTIVE CELL THERAPY
CANCER
IMMUNE CHECKPOINT INHIBITOR
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
TNFΑ
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
id AR_80ad26ef257518e2a441fbbf3ecf6fd9
oai_identifier_str oai:ri.conicet.gov.ar:11336/137148
network_acronym_str AR
network_name_str Argentina
repository_id_str
spelling Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapyMercogliano, María FlorenciaBruni, SofiaMauro, Florencia LucianaElizalde, Patricia VirginiaSchillaci, RoxanaADOPTIVE CELL THERAPYCANCERIMMUNE CHECKPOINT INHIBITORIMMUNOTHERAPYMONOCLONAL ANTIBODYTNFΑhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Tumor necrosis factor alpha (TNFα) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNFα has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages, dendritic cells, natural killer (NK) cells, and B and T lymphocytes. Within the tumor microenvironment, however, TNFα is one of the main mediators of cancer-related inflammation. It is involved in the recruitment and differentiation of immune suppressor cells, leading to evasion of tumor immune surveillance. These characteristics turn TNFα into an attractive target to overcome therapy resistance and tackle cancer. This review focuses on the diverse molecular mechanisms that place TNFα as a source of resistance to immunotherapy such as monoclonal antibodies against cancer cells or immune checkpoints and adoptive cell therapy. We also expose the benefits of TNFα blocking strategies in combination with immunotherapy to improve the antitumor effect and prevent or treat adverse immune-related effects.Fil: Mercogliano, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Ciudad Universitaria. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales; ArgentinaFil: Bruni, Sofia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Mauro, Florencia Luciana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Elizalde, Patricia Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Schillaci, Roxana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaMDPI2021-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/137148Mercogliano, María Florencia; Bruni, Sofia; Mauro, Florencia Luciana; Elizalde, Patricia Virginia; Schillaci, Roxana; Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy; MDPI; Cancers; 13; 3; 2-2021; 1-332072-6694CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2072-6694/13/3/564info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13030564info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2024-05-08T14:28:58Zoai:ri.conicet.gov.ar:11336/137148instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982024-05-08 14:28:58.413CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
title Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
spellingShingle Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
Mercogliano, María Florencia
ADOPTIVE CELL THERAPY
CANCER
IMMUNE CHECKPOINT INHIBITOR
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
TNFΑ
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
title_short Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
title_full Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
title_fullStr Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
title_full_unstemmed Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
title_sort Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy
dc.creator.none.fl_str_mv Mercogliano, María Florencia
Bruni, Sofia
Mauro, Florencia Luciana
Elizalde, Patricia Virginia
Schillaci, Roxana
author Mercogliano, María Florencia
author_facet Mercogliano, María Florencia
Bruni, Sofia
Mauro, Florencia Luciana
Elizalde, Patricia Virginia
Schillaci, Roxana
author_role author
author2 Bruni, Sofia
Mauro, Florencia Luciana
Elizalde, Patricia Virginia
Schillaci, Roxana
author2_role author
author
author
author
dc.subject.none.fl_str_mv ADOPTIVE CELL THERAPY
CANCER
IMMUNE CHECKPOINT INHIBITOR
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
TNFΑ
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
topic ADOPTIVE CELL THERAPY
CANCER
IMMUNE CHECKPOINT INHIBITOR
IMMUNOTHERAPY
MONOCLONAL ANTIBODY
TNFΑ
https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
description Tumor necrosis factor alpha (TNFα) is a pleiotropic cytokine known to have contradictory roles in oncoimmunology. Indeed, TNFα has a central role in the onset of the immune response, inducing both activation and the effector function of macrophages, dendritic cells, natural killer (NK) cells, and B and T lymphocytes. Within the tumor microenvironment, however, TNFα is one of the main mediators of cancer-related inflammation. It is involved in the recruitment and differentiation of immune suppressor cells, leading to evasion of tumor immune surveillance. These characteristics turn TNFα into an attractive target to overcome therapy resistance and tackle cancer. This review focuses on the diverse molecular mechanisms that place TNFα as a source of resistance to immunotherapy such as monoclonal antibodies against cancer cells or immune checkpoints and adoptive cell therapy. We also expose the benefits of TNFα blocking strategies in combination with immunotherapy to improve the antitumor effect and prevent or treat adverse immune-related effects.
publishDate 2021
dc.date.none.fl_str_mv 2021-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/137148
Mercogliano, María Florencia; Bruni, Sofia; Mauro, Florencia Luciana; Elizalde, Patricia Virginia; Schillaci, Roxana; Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy; MDPI; Cancers; 13; 3; 2-2021; 1-33
2072-6694
CONICET Digital
CONICET
url http://hdl.handle.net/11336/137148
identifier_str_mv Mercogliano, María Florencia; Bruni, Sofia; Mauro, Florencia Luciana; Elizalde, Patricia Virginia; Schillaci, Roxana; Harnessing tumor necrosis factor alpha to achieve effective cancer immunotherapy; MDPI; Cancers; 13; 3; 2-2021; 1-33
2072-6694
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/2072-6694/13/3/564
info:eu-repo/semantics/altIdentifier/doi/10.3390/cancers13030564
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1799196467628343296
score 15,812455

Registos relacionados